Form 4: Insmed Inc. CEO William Lewis Executes Stock Sales Under 10b5-1 Plan

Insmed Inc.'s Chair and CEO, William Lewis, executed multiple sales of common stock on May 20, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• William Lewis, Chair and CEO of Insmed Inc., reported the sale of common stock on May 20, 2025.
• The transactions were executed under a pre-arranged 10b5-1 trading plan.
• Multiple sales occurred at varying prices, ranging from $66.34 to $68.59 per share.
• Lewis also exercised stock options at a price of $10.85.
• Following the reported transactions, Lewis directly owns 314,230 shares of common stock.
• Lewis indirectly owns 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
• The Katie Procter Dynasty Trust also holds 163,990 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Executive stock sales are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares over a period of time while avoiding accusations of trading on non-public information. Investors often monitor these transactions for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages, including stock options and equity grants, are standard practice in the pharmaceutical industry to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a common and accepted method for executives to manage their personal finances while complying with insider trading regulations.
• Comparing the volume and frequency of insider sales at Insmed to those of its peers (e.g., Vertex Pharmaceuticals, BioMarin Pharmaceutical) could provide additional context.

Stakeholder Impact

• Shareholders may interpret insider sales as a signal, although sales under a 10b5-1 plan are generally viewed as less informative.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Insmed Inc, William Lewis, stock sale, Form 4, 10b5-1 trading plan, executive compensation, insider trading, common stock, stock options